Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
The Korean Journal of Internal Medicine ; : 128-131, 2004.
Article in English | WPRIM | ID: wpr-122271

ABSTRACT

Gallbladder perforation is an almost exclusive complication of cholecystitis, which accompanies severe inflammation of the gallbladder with or without cholelithiasis. Whether it is of a calculous or acalculous origin, gallbladder perforation, as a complication of acute cholecystitis, has common symptoms, signs, laboratory data, radiological findings and treatment modalities. Even though many reports of gallbladder perforation have been published, there are few reports of gallbladder perforation without any clinical and radiological indications. We experienced a case of a 70-year-old woman with acute abdomen, which was found to be peritonitis caused by spontaneous gallbladder perforation that was devoid of clues suggesting this condition. Although rare and unusual, this case shows that this disorder should be considered in elderly patients presenting with peritonitis with an unknown etiology.


Subject(s)
Aged , Female , Humans , Gallbladder Diseases/complications , Peritonitis/diagnosis , Tomography, X-Ray Computed , Ultrasonography, Interventional
2.
The Korean Journal of Gastroenterology ; : 468-475, 2003.
Article in English | WPRIM | ID: wpr-96877

ABSTRACT

BACKGROUND/AIMS: Genetic polymorphism of cytochrome P450 CYP2C19 influences the efficacy of proton pump inhibitor (PPI) in Helicobacter pylori (H. pylori) eradication therapy. We investigated the difference in the cure rates of H. pylori infection by triple (rabeprazole plus amoxacillin and clarithromycin) therapy in relation to CYP2C19 genotype status. METHODS: One hundred and sixteen H. pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b.i.d., 1,000 mg amoxacillin b.i.d. and 500 mg of clarithromycin b.i.d. for one week. The genotype of CYP2C19 was determined by a PCR-restriction fragment length polymorphism method. RESULTS: According to the univariate analysis, heterozygous extensive metabolizers (hetero EMs) and poor metabolizers (PMs) showed the highest (87.0%) and the lowest (80.0%) eradication rates, respectively. The difference in the therapeutic efficacy of rabeprazole among the different CYP2C19 genotypes was insignificant. With regard to gender, age and smoking history in relation to eradication rate, a statistical significance was noted only with age with odds ratio of 1.063 and p-value of 0.0202. CONCLUSIONS: In the eradication therapy of H. pylori, no statistically significant difference in therapeutic efficacy of rabeprazole was found among different CYP2C19 genotypes.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , 2-Pyridinylmethylsulfinylbenzimidazoles , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Benzimidazoles/administration & dosage , Clarithromycin/administration & dosage , Drug Therapy, Combination , Duodenal Ulcer/drug therapy , Genotype , Helicobacter Infections/drug therapy , Helicobacter pylori , Mixed Function Oxygenases/genetics , Omeprazole/analogs & derivatives , Proton Pumps/antagonists & inhibitors , Stomach Ulcer/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL